Since its approval in 2018 by the US Food and Drug Administration, peptide receptor radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine tumors. Lutetium-177-DOTATATE, ...
The radiopharmaceutical consists of a radioactive molecule – in this case terbium-161 linked to a ligand. This ligand recognises proteins on the tumour cell, allowing highly targeted cancer treatment.
Combination of ZG005 with etoposide and cisplatin (EP) vs. EP as the first-line therapy for advanced neuroendocrine carcinoma: A randomized, multicenter, phase I/II trial. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results